doctors
nurses
new patient coordinator
other health care professionals
The following list represents only a fraction of articles published by Dr. Guido Tricot and highlights only those published in 1995 or later. If you would like to see a complete list of Dr. Tricot's publications, please contact us.
G Tricot, M H Cottler-Fox, G Calandra. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplantation. 22 June 2009.
Siqing Wang, Guido Tricot, Lei Shi, Wei Xiong, Zhaoyang Zeng, Hongwei Xu, Maurizio Zangari, Bart Barlogie, John D. Shaughnessy, Jr, and Fenghuang Zhan. RAR{alpha}2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009 May 20.
Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy J, Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008 Mar; 140(6):625-34.
Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J,
Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y,
Hoering A, Crowley J, Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008 Jan 1;111 (1):94-100. [Epub 2007 Sep 25]
Ronald Walker, Bart Barlogie, Jeffrey Haessler, Guido Tricot, Elias Anaissie, John D. Shaughnessy Jr, Joshua Epstein, Rudy van Hemert, Eren Erdem, Antje Hoering, John Crowley, Ernest Ferris, Klaus Hollmig, Frits van Rhee, Maurizio Zangari, Mauricio Pineda-Roman, Abid Mohiuddin, Shmuel Yaccoby, Jeffrey Sawyer, and Edgardo J. Angtuaco Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications. J Clin Oncol. 2007; 25 (9): 1121-1128.
Bart Barlogie, Elias Anaissie, Frits van Rhee, Jeffrey Haessler, Klaus Hollmig, Mauricio Pineda-Roman, Michele Cottler-Fox, Abid Mohiuddin, Yazan Alsayed, Guido Tricot, Vanessa Bolejack, Maurizio Zangari, Joshua Epstein, Nathan Petty, Douglas Steward, Bonnie Jenkins, Jennifer Gurley, Ellen Sullivan, John Crowley and John D. Jr Shaughnessy. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, Volume 138, Issue 2, Page 176-185, Jul 2007
Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna
SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F,
Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene
expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007; 109 (6): 2276-2284. Epub 2006 Nov 14.
Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy Jr JD. Gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007; 109: 1692-1700.
F Zhan, J Sawyer, G Tricot. The role of cytogenetics in myeloma. Leukemia 2006; 20, 1484–1486.
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy Jr JD. The molecular classification of multiple myeloma. Blood 2006; 108(6): 2020-2028.
Barlogie B, Shaughnessy J, Bolejack V, Tricot G. The Thalidomide Confusion in Multiple Myeloma. The American Journal of Hematology/Oncology. 2006; 5: 404-412.
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E,
Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 9; 354(10): 1076-8.
Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica 2006; 91(7): 964-967.
Tricot G. Multiple Myeloma and Other Plasma Cell Disorders. Hematology: Basic Principles and Practice 4th edition. Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P (eds). Elseiver Inc. 2005, 1501-1535.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno Spagnoli G, Shaughnessy J, Tricot GJ. NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005 May 15; 105 (10):3939-44. Epub 2005 Jan 25.
Lee C, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004; 33(8): 823-828.
Tricot G, Barlogie B, Van Rhee F. Treatment Advances in Multiple Myeloma. Br J Haematol. 2004; 125(1): 24-30.
Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant. 2004; 33(9): 955-962.
Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Choon-Kee L, Thertulien R, Talamo G, Thomas T, van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology. 2004; 126: 715-721.
Morris C, Siegel E, Barlogie B, Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34+ cells in elderly patients (³70 years) with multiple myeloma: influence of age, prior therapy, platelet count, and mobilization regimen. Br J of Haematology, 2003: 120 (3):413-23.
Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003; 31:73-80.
Lee C, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003; 21(14): 2732-2739.
Shaughnessy J, Barlogie B, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M. Jacobson J, Crowley J, Tricot G. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood. 2003; 101(10):3849-3856. Epub 2003 Jan 16
Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003; 123(3): 484-489.
Zhan F, Hardin K, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, and Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 99: 1745-1757, 2002.
Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of Doxorubicin in myeloma patients receiving Thalidomide: implications for therapy. Blood, 100: 1168-1171, 2002.
Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie A, Morris C, Van Rhee F, Cottler-Fox M, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage for high-risk patients with myeloma in relapse. Bone Marrow Transplantation, 2002; 30:873-878.
Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Morris C, Barlogie B, Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J of Haematology, 2002: Sep; 118(4):1041-7.
Badros A, Barlogie B, Morris C, Deskian R, Martin SR, Munshi N, Zangari M, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood, 97: 2574-2579, 2001.
Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E, Munshi N, and Tricot G. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British Journal of Haematology, 114: 600-607, 2001.
Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, and Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98: 492-494, 2001.
Zangari M, Anaissie E, Badros A, Desikan R, Gopal A, Morris C, Toor A, Siegel E, Fink L, Barlogie B, and Tricot, G. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 98: 1614-1615, 2001.
Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver M, Fassas, A, McConnell S, Muwalla F, Barris Y, Anaissie E, Munshi N, Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology, 114: 822-829, 2001.
Tricot G, Spencer T, Spoon D, Sawyer J, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long term (> event-free survival in multiple myeloma patients following tandem autotransplants). British Journal of Haematology, 116: 211-217, 2001.
Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet, 355: 248-250, 2000.
Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Nauckle S, Ayers D, Spoon D, Vesole D, Tricot G, and Barlogie B. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood, 93: 51-54, 1999.
Tricot G, Sawyer J, and Barlogie B. The role of cytogenetics in myeloma. Myeloma: Biology and Management (Malpas JS, Bergsagel DE, Kyle RA, and Anderson KC. eds) Oxford Medical Publications, 1997.
Tricot G, Sawyer J, Jagannath S, Desikan K, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, and Barlogie B. The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. Journal of Clinical Oncology, 15(7): 2659-2666, 1997.
Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, and Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89(3): 789-793, 1997.
Tricot G, Vesole D, Jagannath S, Hilton J, Munshi N, and Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood, 87(3): 1196-1198, 1996.
Tricot G, Alberts D, Johnson C, Roe D, Dorr R, Bracy D, Vesole D, Jagannath S, Meyers R, and Barlogie B. Safety of Autotransplants with High-Dose Melphalan in Renal Failure: A Pharmacokinetic and Toxicity Study. Clinical Cancer Research, 2: 947-952, 1996.
Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, and Sawyer J. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86(11): 4250-4256, 1995.
Tricot G, Jagannath S, Vesole DH, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, and Barlogie B. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood, 85(2): 588-596, 1995.
